# Long-Term Extension Study With Eptinezumab as Preventive Treatment in Participants With Migraine in Japan

> **NCT05064371** · PHASE3 · COMPLETED · sponsor: **H. Lundbeck A/S** · enrollment: 160 (actual)

## Conditions studied

- Migraine

## Interventions

- **DRUG:** Eptinezumab

## Key facts

- **NCT ID:** NCT05064371
- **Lead sponsor:** H. Lundbeck A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-09-21
- **Primary completion:** 2024-06-08
- **Final completion:** 2024-06-08
- **Target enrollment:** 160 (ACTUAL)
- **Last updated:** 2026-01-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05064371

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05064371, "Long-Term Extension Study With Eptinezumab as Preventive Treatment in Participants With Migraine in Japan". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05064371. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*